Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 11/20 | 0.65 |
| ▸ | TGFBR2 | P37173 | 8/20 | 0.65 |
| ▸ | PIK3C3 | Q8NEB9 | 7/20 | 0.41 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.41 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.41 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17840702 | 0.91 | TGFBR1 (0.78) | TGFBR1TGFBR2PIK3C3 | |
| SCHEMBL17840766 | 0.85 | TGFBR1 (0.62) | TGFBR1TGFBR2PIK3C3TLR9TLR8 | |
| SCHEMBL17840857 | 0.84 | TGFBR1 (0.67) | TGFBR1TGFBR2PIK3C3TLR9TLR8 | |
| SCHEMBL17840603 | 0.83 | TGFBR1 (0.64) | TGFBR1TGFBR2AAK1 | |
| SCHEMBL17840645 | 0.82 | TGFBR1 (0.78) | TGFBR1TGFBR2PIK3C3TLR8TLR7 | |
| SCHEMBL17840757 | 0.82 | TGFBR1 (0.78) | TGFBR1TGFBR2PIK3C3 | |
| SCHEMBL17840749 | 0.81 | TGFBR1 (0.77) | TGFBR1TGFBR2PIK3C3 | |
| SCHEMBL17840566 | 0.81 | TGFBR1 (0.83) | TGFBR1TGFBR2PIK3C3 | |
| SCHEMBL17840688 | 0.81 | TGFBR1 (0.73) | TGFBR1TGFBR2PIK3C3CYP3A4AAK1 | |
| SCHEMBL17840808 | 0.80 | TGFBR1 (0.57) | TGFBR1TGFBR2TLR9TLR8TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3237415-A1 | TGF RECEPTOR ANTAGONISTS | Bristol-Myers Squibb Company (US) | 2017-11-01 | — | — | EP | disclosed |
| US-9708316-B2 | TGFβR antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-07-18 | — | — | US | disclosed |
| WO-2016106266-A1 | TGFβ RECEPTOR ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-06-30 | — | — | WO | disclosed |
| WO-2016106266-A1 | TGFβ RECEPTOR ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-06-30 | — | — | WO | disclosed |
| US-20160176871-A1 | TGF BETA R ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY | 2016-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160176871-A1 | TGF BETA R ANTAGONISTS | TGFBR2, TGFBR1, TGFB1 | TGFBR1 2/4885TGFBR2 1/4885PIK3C3 2608/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.